Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
Holding SGHT?
Track your performance easily
SGHT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.70 - $8.45
Previous Close$4.59
Volume204.76K
Average Volume (3M)182.99K
Market Cap
$232.96M
Enterprise Value$148.55M
Total Cash (Recent Filing)$118.56M
Total Debt (Recent Filing)$34.15M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Mar 20, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding50,754,616
10 Day Avg. Volume337,643
30 Day Avg. Volume182,991
Standard Deviation0.30
R-Squared0.20
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.26
Price to Sales (P/S)2.93
Price to Cash Flow (P/CF)160.90
P/FCF Ratio39.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit2.15
Enterprise Value/Ebitda-3.37
Forecast
1Y Price Target
$5.38Price Target Upside27.19% Upside
Rating ConsensusHold
Number of Analyst Covering5
Sight Sciences News
PremiumCompany Announcements
Sight Sciences Reports Modest Growth and Optimistic Outlook
PremiumCompany Announcements
Sight Sciences Reports Revenue Growth and Leadership Change
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe balance sheet is solid with a significant cash reserve, indicating no immediate liquidity risk for Sight Sciences.
Market OpportunityOMNI still has potential to take market share in the underpenetrated standalone market, providing some upside opportunity.
Revenue Growth PotentialTearCare submissions are ongoing, and payor wins could occur which would likely catalyze Dry Eye revenue growth.
Bears Say
Market UncertaintyThe downgrade to a Hold rating and lowering of the price target reflects uncertainty and capped upside for Sight Sciences.
Regulatory ChallengesCMS did not confirm device-intensive reimbursement for canaloplasty in the ASC setting, which could have leveled the playing field and afforded Sight some price taking opportunity.
Revenue PerformanceSGHT's Q3 came in below expectations with pressure stemming from its Surgical Glaucoma business.
---
Ownership Overview
36.61% Insiders
5.34% Mutual Funds
0.19% Other Institutional Investors
51.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $1.70 and its highest was $8.45 in the past 12 months.
What is Sight Sciences’s market cap?
Currently, no data Available
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Mar 20, 2025 which is in 117 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.208 by -$0.012.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -$0.22.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 50,754,616 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.208. Following the earnings report the stock price went down -9.615%.
Which hedge fund is a major shareholder of Sight Sciences?
Among the largest hedge funds holding Sight Sciences’s share is EntryPoint Capital, LLC. It holds Sight Sciences’s shares valued at 35K.
---
Sight Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.38 (27.19% Upside)
$5.38 (27.19% Upside)
Hedge Fund Trend
Increased
By 5.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $696.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
161.53%
12-Months-Change
Fundamentals
Return on Equity
-45.36%
Trailing 12-Months
Asset Growth
-18.71%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company's product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company's non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
---
SGHT Company Deck
---
SGHT Earnings Call
Q3 2024
0:00 / 0:00
---
SGHT Stock 12 Month Forecast
Average Price Target
$5.38
▲(27.19% Upside)
Technical Analysis
Best Analysts Covering SGHT
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
+17.04%
reiterated a buy rating 12 days ago
Copying Thomas Stephan's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of +17.04% per trade.
---